The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60 - PubMed (original) (raw)
The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60
K-A Chaiwatanasirikul et al. Cell Death Dis. 2011.
Abstract
The product of the CLU gene promotes or inhibits tumourigenesis in a context-dependent manner. It has been hypothesised that different CLU isoforms have different and even opposing biological functions, but this theory has not been experimentally validated. Here we show that molecules involved in survival pathways are differentially modulated by the intracellular or secreted forms of CLU. Secreted CLU, which is selectively increased after transformation, activates the survival factor AKT, whereas intracellular CLU inhibits the activity of the oncogenic transcription factor nuclear factor kappa B. Furthermore, intracellular CLU is inactivated by the pro-proliferative and pro-survival activity of the chaperone protein HSP60 in neuroblastoma cells by forming a physical complex. Thus, localisation is key for CLU physiology, explaining the wide range of effects in cell survival and transformation.
Figures
Figure 1
Secreted CLU is unable to modulate NF-_κ_B activity. (a) SHSY5Y or (b) LA-N-1 neuroblastoma cells were transfected with a NF-_κ_B luciferase reporter vector, incubated with control or CLU-conditioned medium, as indicated in the bottom of the graphs, and subjected to luciferase assays. Activation of NF-_κ_B by TNF served as a positive control for the assay. Relative luciferase activity is indicated on the y axis. (c) SHSY5Y or (d) LA-N-1 cells were co-transfected with the NF-_κ_B reporter vector and a control (empty MIG), or CLU, expressing plasmid with or without TNF. Error bars indicate standard deviations, and significance is indicated by the P. NS indicates that the difference is not significant
Figure 2
Secreted CLU modulates AKT and is increased relative to intracellular CLU during transformation. (a) Western blot analysis of phosphorylated and total AKT in the indicated neuroblastoma cell lines. Hours of stimulation with control or CLU-conditioned media (CLU-MIG) are indicated on the top of the blots. (b) Western blot analysis of phosphorylated and total ERK in the indicated neuroblastoma cell lines. Hours of stimulation with the control or CLU-conditioned media are indicated on the top of the blots. (c) Western blot analysis of CLU expression in the isogenic cell lines WI38 (primary human fibroblasts) and VA13 (SV40-transformed WI38). (d) Western blot analysis of the expression of CLU in the adrenal glands and tumours resected from MYCN transgenic mice. pCLU, precursor CLU; sCLU, secreted CLU
Figure 3
Identification of HSP60 as a CLU-interacting protein. (a) proteins pulled down by the indicated GST fusion proteins were visualised by colloidal Coomassie staining. A protein of ∼60 kDa interacting with full length and alpha chain CLU (indicated by the arrow) was excised from the gel and subjected to mass spectrometry analysis. (b) Proteins pulled down by the indicated fusion proteins were subjected to western blot analysis with a HSP60 antibody. (c) Co-immunoprecipitation assay. 293 cells were transfected with control or CLU plasmids, lysed and immunoprecipitated with CLU, HSP60 or control antibodies. After transfer to nitrocellulose, immune complexes were subjected to western blot analysis with a HSP60 antibody. Specific binding proteins are indicated by an asterisk
Figure 4
HSP60 and CLU form a complex in neuroblastoma cells. (a) Western blot analysis of LA-N-1 cell lysate showing expression of CLU at different time points after a sub-lethal heat shock. Actin and HSP60 expression were used as a loading control. (b) Reciprocal co-immunoprecipitation of heath shocked LA-N-1 cells with CLU, HSP60 and control antibodies. The native CLU/HSP60 complex is indicated by the arrows. Inp, input
Figure 5
HSP60 positively regulates proliferation and survival of established and primary neuroblastoma cell lines. (a) Western blot analysis to monitor the expression of HSP60 in three SHSY-5Y cell clones obtained after infection with shRNA control (+) or HSP60 (−) targeting viruses. Quantification of HSP60 expression relative to actin is shown in the bottom of the gel. (b) Fluorescence microscopy analysis to visualise GFP expression of the SHSY-5Y clones shown in (a). Pictures were taken the day after infections (t 0) or after 6 days in culture (t 6). (c) Quantification of the experiment shown in (b). (d) Western blot analysis of primary human neuroblastoma cells infected with a control (+) or HSP60 (−) shRNA lentivirus. Relative expression of HSP60 is indicated at the bottom of the gel. (e) Proliferation assay of primary human neuroblastoma cells after ablation of HSP60 expression. (f) PI staining and FACS analysis to assess cell cycle profile and DNA fragmentation in primary human neuroblastoma cells after downregulation of HSP60. Percentages of cells in the different phases of the cell cycle or subG1 DNA (fragmented DNA) are indicated
Figure 6
HSP60 is a negative prognostic marker in human neuroblastoma. (a) Box plot showing the significant association between MYCN amplification and HSP60 expression in 101 neuroblastoma patients. Data were mined through the Oncomine website (
). Kaplan–Meier survival curves were generated from the Oncogenomics website (
http://pob.abcc.ncifcrf.gov/cgi-bin/JK
) using the data extracted from the Oberthuer. Black dots indicate outliers. (b) and Seeger (c) affymetrix datasets
Figure 7
Downregulation of CLU rescues apoptosis induced by ablation of HSP60. Cell cycle profiles and DNA fragmentation (indicated by percentages of subG1 DNA, in bold) were assessed by flow cytometry after knockdown of CLU and HSP60 in SHSY-5Ycell clones. The experiment was repeated twice. (a) experiment 1; (b) experiment 2. Quantification of the percentages of cells showing fragmented DNA in the different conditions is shown in the right of each panel
Figure 8
HSP60 signalling is upstream of CLU and NF-_κ_B in neuroblastoma. (a) SHSY5Y or (b) primary human neuroblastoma cells (HNB) were stably infected with scrambled or HSP60 shRNA lentiviruses and subsequently transfected with a NF-_κ_B reporter vector. Luciferase assays show reduced NF-_κ_B activity in the HSP60-interfered cells as compared with the scrambled infected, control cells. Western blot analyses to verify HSP60 downregulation are shown in the right. (c) Analysis of co-expression of HSP60 and NF-_κ_B target genes (boxed) in neuroblastoma patients. The analysis was carried out using tools in the Oncomine website and is based upon the affymetrix datasets indicated in the legend. (d) Western blot analysis showing increased CLU expression in the primary neuroblastoma cells (HNB) after shRNA-induced downregulation of HSP60. (e) Model of the HSP60–CLU axis operating in neuroblastoma cells and the outcome of its manipulation
Similar articles
- The clusterin paradigm in prostate and breast carcinogenesis.
Rizzi F, Bettuzzi S. Rizzi F, et al. Endocr Relat Cancer. 2010 Jan 29;17(1):R1-17. doi: 10.1677/ERC-09-0140. Print 2010 Mar. Endocr Relat Cancer. 2010. PMID: 19903745 Review. - Non-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-κB signaling pathway.
Prochnow H, Gollan R, Rohne P, Hassemer M, Koch-Brandt C, Baiersdörfer M. Prochnow H, et al. PLoS One. 2013 Sep 20;8(9):e75303. doi: 10.1371/journal.pone.0075303. eCollection 2013. PLoS One. 2013. PMID: 24073260 Free PMC article. - Transcriptome-Based Analysis of Molecular Pathways for Clusterin Functions in Kidney Cells.
Dairi G, Guan Q, Roshan-Moniri M, Collins CC, Ong CJ, Gleave ME, Nguan CY, Du C. Dairi G, et al. J Cell Physiol. 2016 Dec;231(12):2628-38. doi: 10.1002/jcp.25415. Epub 2016 Jun 15. J Cell Physiol. 2016. PMID: 27155085 - Clusterin gene is predominantly regulated by histone modifications in human colon cancer and ectopic expression of the nuclear isoform induces cell death.
Deb M, Sengupta D, Rath SK, Kar S, Parbin S, Shilpi A, Pradhan N, Bhutia SK, Roy S, Patra SK. Deb M, et al. Biochim Biophys Acta. 2015 Aug;1852(8):1630-45. doi: 10.1016/j.bbadis.2015.04.021. Epub 2015 Apr 25. Biochim Biophys Acta. 2015. PMID: 25917404 - Chapter 4: Regulation of Clusterin activity by calcium.
Pajak B, Orzechowski A. Pajak B, et al. Adv Cancer Res. 2009;104:33-58. doi: 10.1016/S0065-230X(09)04004-4. Adv Cancer Res. 2009. PMID: 19878772 Review.
Cited by
- Heat Shock Proteins, a Double-Edged Sword: Significance in Cancer Progression, Chemotherapy Resistance and Novel Therapeutic Perspectives.
Kunachowicz D, Król-Kulikowska M, Raczycka W, Sleziak J, Błażejewska M, Kulbacka J. Kunachowicz D, et al. Cancers (Basel). 2024 Apr 14;16(8):1500. doi: 10.3390/cancers16081500. Cancers (Basel). 2024. PMID: 38672583 Free PMC article. Review. - Heat shock protein paradigms in cancer progression: future therapeutic perspectives.
Tausif YM, Thekkekkara D, Sai TE, Jahagirdar V, Arjun HR, Meheronnisha SK, Babu A, Banerjee A. Tausif YM, et al. 3 Biotech. 2024 Apr;14(4):96. doi: 10.1007/s13205-024-03951-6. Epub 2024 Mar 5. 3 Biotech. 2024. PMID: 38449709 Review. - The role and function of CLU in cancer biology and therapy.
Zhang Y, Lv X, Chen L, Liu Y. Zhang Y, et al. Clin Exp Med. 2023 Sep;23(5):1375-1391. doi: 10.1007/s10238-022-00885-2. Epub 2022 Sep 13. Clin Exp Med. 2023. PMID: 36098834 Review. - The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer.
Inigo JR, Chandra D. Inigo JR, et al. J Hematol Oncol. 2022 Jul 21;15(1):98. doi: 10.1186/s13045-022-01317-0. J Hematol Oncol. 2022. PMID: 35864539 Free PMC article. Review. - Mitochondrial chaperones in human health and disease.
Bahr T, Katuri J, Liang T, Bai Y. Bahr T, et al. Free Radic Biol Med. 2022 Feb 1;179:363-374. doi: 10.1016/j.freeradbiomed.2021.11.015. Epub 2021 Nov 12. Free Radic Biol Med. 2022. PMID: 34780988 Free PMC article. Review.
References
- Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;13:12–19. - PubMed
- Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol. 2002;34:427–431. - PubMed
- Han BH, DeMattos RB, Dugan LL, Kim-Han JS, Brendza RP, Fryer JD, et al. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med. 2001;7:338–343. - PubMed
- Gleave M, Chi KN. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann NY Acad Sci. 2005;1058:1–15. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous